ALPHARETTA, Ga., Nov. 08, 2016 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, announced that Daniel H. White, Chief Executive Officer and President of Clearside, will present at the 2016 Stifel Healthcare Conference on Wednesday, November 16, 2016 at 3:00pm EST at the Lotte New York Palace in New York, NY.
The presentation will be webcast live and may be accessed by visiting Clearside’s website at http://ir.clearsidebio.com. A replay of the webcast will be available for 30 business days.
About Clearside Biomedical, Inc.
Clearside Biomedical, Inc., headquartered in Alpharetta, GA, is a publicly traded, ophthalmic biopharmaceutical company that envisions a world without blindness. Clearside relentlessly pursues transformative, elegant, precise solutions to restore and preserve vision. Clearside is developing advanced clinical and pre-clinical product candidates using a proprietary treatment approach offering unprecedented access to the back of the eye through the suprachoroidal space (SCS™). This offers potentially significant treatment benefit to patients suffering from sight threatening diseases like uveitis, retinal vein occlusion, wet age-related macular degeneration and diabetic macular edema. To learn more about how Clearside is changing ophthalmology, please visit us at www.clearsidebio.com.
Contacts
Company:
Charles Deignan
Chief Financial Officer
678-270-4005
charlie.deignan@clearsidebio.com
Investors:
Matthew BeckThe Trout Group
646-378-2933
mbeck@troutgroup.com
Clearside Biomedical, Inc.
